(a) Encouragement of applications with respect to clinical trials
(1)If, in the determination of the Secretary, there is preliminary evidence that a new drug has effectiveness in humans with respect to the prevention or treatment of acquired immune deficiency syndrome, the Secretary shall, through statements published in the Federal Register—
(A)announce the fact of such determination; and
(B)with respect to the new drug involved, encourage an application for an exemption for investigational use of the new drug under regulations issued under section
355(i) of title
(A)The AIDS Research Advisory Committee established pursuant to section
300cc–3 of this title shall make recommendations to the Secretary with respect to new drugs appropriate for determinations described in paragraph (1).
(B)The Secretary shall, as soon as is practicable, determine the merits of recommendations received by the Secretary pursuant to subparagraph (A).
(b) Encouragement of applications with respect to treatment use in circumstances other than clinical trials
(1)In the case of a new drug with respect to which the Secretary has made a determination described in subsection (a) of this section and with respect to which an exemption is in effect for purposes of section
355(i) of title
21, the Secretary shall—
(A)as appropriate, encourage the sponsor of the investigation of the new drug to submit to the Secretary, in accordance with regulations issued under such section, an application to use the drug in the treatment of individuals—
(i)who are infected with the etiologic agent for acquired immune deficiency syndrome; and
(ii)who are not participating in the clinical trials conducted pursuant to such exemption; and
(B)if such an application is approved, encourage, as appropriate, licensed medical practitioners to obtain, in accordance with such regulations, the new drug from such sponsor for the purpose of treating such individuals.
(2)If the sponsor of the investigation of a new drug described in paragraph (1) does not submit to the Secretary an application described in such paragraph (relating to treatment use), the Secretary shall, through statements published in the Federal Register, encourage, as appropriate, licensed medical practitioners to submit to the Secretary such applications in accordance with regulations described in such paragraph.
(c) Technical assistance with respect to treatment use
In the case of a new drug with respect to which the Secretary has made a determination described in subsection (a) of this section, the Secretary may, directly or through grants or contracts, provide technical assistance with respect to the process of—
(1)submitting to the Secretary applications for exemptions described in paragraph (1)(B) of such subsection;
(2)submitting to the Secretary applications described in subsection (b) of this section; and
(3)with respect to sponsors of investigations of new drugs, facilitating the transfer of new drugs from such sponsors to licensed medical practitioners.
(d) “New drug” defined
For purposes of this section, the term “new drug” has the meaning given such term in section
321 of title
A prior section
300cc–12, act July 1, 1944, § 2313, was successively renumbered by subsequent acts and transferred, see section
238j of this title.
1993—Subsec. (a)(2)(A). Pub. L. 103–43substituted “AIDS Research Advisory Committee” for “AIDS Clinical Research Review Committee”.
The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.
The most recent Classification Table update that we have noticed was Tuesday, August 13, 2013
An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.
Description of Change
Statutes at Large
LII has no control over and does not endorse any external Internet site that contains links to or references LII.